Publication Name	World Journal of Gastroenterology
Manuscript ID	11227
Country	Japan

Received	2014-05-10 15:16
Peer-Review Started	2014-05-10 21:39
To Make the First Decision	2014-06-10 13:24
Return for Revision	2014-06-15 15:39
Revised	2014-06-23 20:07
Second Decision	2014-07-22 16:57
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-07-22 18:19
Articles in Press	2014-07-22 18:34
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-01-05 19:50
Publish the Manuscript Online	2015-01-20 20:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: First case report
Manuscript Source	Unsolicited Manuscript
All Author List	Katsuyoshi Tamaki and Akihiko Okubo
Funding Agency and Grant Number
Corresponding Author	Katsuyoshi Tamaki, MD, PhD, Department of Hepatology, Tourai-kai Okubo Hospital, 2-30 Omichi, Tokushima 770-0924, Japan. cer.tamaki@gmail.com
Key Words	Simeprevir; Chronic hepatitis C; Interstitial pneumonitis; Peg-interferon-α; Adverse events
Core Tip	Simeprevir, which is a second-generation protease inhibitor, has shown clinically favorable safety and tolerability profiles. One serious adverse event associated with IFN therapy is interstitial pneumonitis. We experienced a patient with interstitial pneumonitis that was induced by simeprevir with PEG-IFN and RBV therapy for chronic hepatitis C in the early stages of therapy (8 weeks after initiating therapy). This is the first case report of interstitial pneumonitis with simeprevir with PEG-IFN and RBV in the world. In addition, it is very interesting that the onset of interstitial pneumonitis was earlier than that in conventional PEG-IFN and RBV therapy.
Publish Date	2015-01-20 20:12
Citation	Tamaki K, Okubo A. Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: First case report. World J Gastroenterol 2015; 21(3): 1009-1013
URL	http://www.wjgnet.com/1007-9327/full/v21/i3/1009.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i3.1009

Full Article (PDF)	WJG-21-1009.pdf
Full Article (Word)	WJG-21-1009.doc
Manuscript File	11227-Review.doc
Answering Reviewers	11227-Answering reviewers.pdf
Copyright License Agreement	11227-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	11227-Language certificate.pdf
Peer-review Report	11227-Peer review(s).pdf
Scientific Misconduct Check	11227-CrossCheck.jpg
Scientific Editor Work List	11227-Scientific editor work list.pdf